Teva Pharmaceuticals USA settles famciclovir clear lawsuit with Novartis
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an settlement with Novartis to resolve unmistakeable suit involving Teva’s U.S. generic story of Novartis’ Famvir® (famciclovir) 125 mg, 250 mg and 500 mg tablets including all claims in support of apparent breaking and damages. Teva launched its generic famciclovir tablets in the U.S. in September 2007.
The show deal releases Teva fitted all close by and subsequent activities in relations with the U.S. marketing and transaction of Teva’s generic famciclovir tablets. Underneath the terms of the concurrence, Teva devise pretend a one-time payment to Novartis in appendix to an ceaseless share on U.S. sales of generic famciclovir.
FOUNTAIN-HEAD Teva Pharmaceutical Industries Ltd.,
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
